# Alfredo Falcone

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/alfredo-falcone/

## Facts

| Field | Value |
| --- | --- |
| Citations | 42,523 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 90 |
| i10-index | 400 |
| Last Known Institution | University of Pisa |
| OpenAlex ID | https://openalex.org/A5012034272 |
| ORCID iD | https://orcid.org/0000-0001-5840-2529 |
| Works | 1,286 |

## Researcher papers

- [FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study](https://scholariq.org/papers/folfoxiri-plus-bevacizumab-versus-folfiri-plus-bevacizumab-as-first-line/)
- [Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-in-combination-with-gemcitabine-and-cisplatin-compared-with/)
- [Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer](https://scholariq.org/papers/initial-therapy-with-folfoxiri-and-bevacizumab-for-metastatic-colorectal-cancer/)
- [MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity](https://scholariq.org/papers/microrna-21-in-pancreatic-cancer-correlation-with-clinical-outcome-and/)
- [Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan](https://scholariq.org/papers/rechallenge-for-patients-with-i-ras-i-and-i-braf-i-wild-type-metastatic/)
- [PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer](https://scholariq.org/papers/pten-expression-and-kras-mutations-on-primary-tumors-and-metastases-in-the/)
- [Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma](https://scholariq.org/papers/four-year-overall-survival-update-from-the-phase-iii-himalaya-study-of/)
- [The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients](https://scholariq.org/papers/the-detection-of-androgen-receptor-splice-variant-7-in-plasma-derived-exosomal/)
- [Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-with-cisplatin-and-fluoropyrimidine-as-first-line-therapy-in/)
- [PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC](https://scholariq.org/papers/pd-l1-mrna-expression-in-plasma-derived-exosomes-is-associated-with-response-to/)
- [Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment](https://scholariq.org/papers/drug-induced-interstitial-lung-disease-during-cancer-therapies-expert-opinion-on/)
- [Correlation of <i>CDA, ERCC1</i>, and <i>XPD</i> Polymorphisms with Response and Survival in Gemcitabine/Cisplatin–Treated Advanced Non–Small Cell Lung Cancer Patients](https://scholariq.org/papers/correlation-of-i-cda-ercc1-i-and-i-xpd-i-polymorphisms-with-response-and/)

## Researcher topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [University of Pisa](https://scholariq.org/institutions/university-of-pisa/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.